Suppr超能文献

肺超声评分能否准确预测表面活性剂替代治疗?系统评价和诊断试验研究的荟萃分析。

Can lung ultrasound score accurately predict surfactant replacement? A systematic review and meta-analysis of diagnostic test studies.

机构信息

Division of Neonatology, Department of Translational Medical Sciences, Università Federico II di Napoli, Naples, Italy.

Department of Public Health, Università Federico II di Napoli, Naples, Italy.

出版信息

Pediatr Pulmonol. 2023 May;58(5):1427-1437. doi: 10.1002/ppul.26337. Epub 2023 Feb 8.

Abstract

BACKGROUND

Clinical and radiographic criteria are traditionally used to determine the need for surfactant therapy in preterm infants. Lung ultrasound is a bedside test that offers a rapid, radiation-free, alternative to this approach.

OBJECTIVE

To conduct a systematic review and meta-analysis to determine the accuracy of a lung ultrasound score (LUS) in identifying infants who would receive at least one surfactant dose. Secondary aims were to evaluate the predictive accuracy for ≥2 doses and the accuracy of a different image classification system based on three lung ultrasound profiles.

METHODS

PubMed, SCOPUS, Biomed Central, and the Cochrane library between January 2011 and December 2021 were searched. Full articles enrolling preterm neonates who underwent lung ultrasound to predict surfactant administration were assessed and analyzed following Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) and QUADAS-2 guidelines.

RESULTS

Seven prospective studies recruiting 697 infants met the inclusion criteria. Risk of bias was generally low. Oxygen requirement, clinical and radiographic signs of respiratory distress syndrome were used as reference standards for surfactant replacement. The summary receiver operator characteristic (sROC) curve for LUS predicting first surfactant dose showed an area under the curve (AUC) = 0.88 (95% confidence interval [CI]: 0.82-0.91); optimal specificity and sensitivity (Youden index) were 0.83 and 0.81 respectively. Pooled estimates of sensitivity, specificity, diagnostic odds ratio, negative predictive value, and positive predictive value for LUS predicting the first surfactant dose were 0.89 (0.82-0.95), 0.86 (0.78-0.95), 3.78 (3.05-4.50), 0.92 (0.87-0.97), 0.79 (0.65-0.92). The sROC curve for the accuracy of Type 1 lung profile in predicting first surfactant dose showed an AUC of 0.88; optimal specificity and sensitivity were both 0.86. Two studies addressing the predictive accuracy of LUS for ≥2 surfactant doses had high heterogeneity and were unsuitable to combine in a meta-analysis.

DISCUSSION

Despite current significant variation in LUS thresholds, lung ultrasound is highly predictive of the need for early surfactant replacement. This evidence was derived from studies with homogeneous patient characteristics and low risk of bias.

摘要

背景

传统上,临床和影像学标准用于确定早产儿是否需要表面活性剂治疗。肺部超声是一种床边检测方法,可替代这种方法,具有快速、无辐射的优点。

目的

进行系统评价和荟萃分析,以确定肺部超声评分(LUS)在识别需要接受至少一剂表面活性剂的婴儿方面的准确性。次要目的是评估预测≥2 剂的准确性和基于三种肺部超声特征的不同图像分类系统的准确性。

方法

检索了 2011 年 1 月至 2021 年 12 月期间的 PubMed、SCOPUS、Biomed Central 和 Cochrane 图书馆。根据系统评价和荟萃分析报告项目(PRISMA-P)和 QUADAS-2 指南评估并分析了纳入早产儿进行肺部超声以预测表面活性剂给药的所有完整文章。

结果

符合纳入标准的有 7 项前瞻性研究共纳入 697 名婴儿。偏倚风险普遍较低。氧需求、呼吸窘迫综合征的临床和影像学征象被用作表面活性剂替代的参考标准。LUS 预测首次表面活性剂剂量的受试者工作特征(ROC)曲线下面积(AUC)为 0.88(95%置信区间 [CI]:0.82-0.91);最佳特异性和敏感性(Youden 指数)分别为 0.83 和 0.81。LUS 预测首次表面活性剂剂量的敏感性、特异性、诊断比值比、阴性预测值和阳性预测值的汇总估计值分别为 0.89(0.82-0.95)、0.86(0.78-0.95)、3.78(3.05-4.50)、0.92(0.87-0.97)、0.79(0.65-0.92)。LUS 预测首次表面活性剂剂量的 Type 1 肺型准确性的 ROC 曲线下面积为 0.88;最佳特异性和敏感性均为 0.86。两项研究评估了 LUS 预测≥2 剂表面活性剂的准确性,但存在很大异质性,不适合进行荟萃分析。

讨论

尽管目前 LUS 阈值存在显著差异,但肺部超声对早期表面活性剂替代的需求具有高度预测性。该证据来自具有同质患者特征和低偏倚风险的研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验